These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 27091611

  • 1. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H, Yang Q, Wang T, Cao Y, Jiang QY, Ma HD, Sun HW, Hou MX, Yang YP, Feng F.
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [Abstract] [Full Text] [Related]

  • 2. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Chen Y, Feng F, Gao X, Wang C, Sun H, Zhang C, Zeng Z, Lu Y, An L, Qu J, Wang F, Yang Y.
    Curr Cancer Drug Targets; 2015 Jul; 15(3):176-87. PubMed ID: 25714700
    [Abstract] [Full Text] [Related]

  • 3. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 4. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C.
    Cancer Lett; 2016 Feb 28; 371(2):171-81. PubMed ID: 26655273
    [Abstract] [Full Text] [Related]

  • 5. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Feb 28; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 6. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

  • 7. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
    Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, Liu Y.
    J Hematol Oncol; 2015 Oct 29; 8():122. PubMed ID: 26514126
    [Abstract] [Full Text] [Related]

  • 8. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y.
    PLoS One; 2014 Oct 29; 9(12):e115565. PubMed ID: 25531114
    [Abstract] [Full Text] [Related]

  • 9. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
    Feng F, Jiang Q, Cao S, Cao Y, Li R, Shen L, Zhu H, Wang T, Sun L, Liang E, Sun H, Chai Y, Li X, Liu G, Yang R, Yang Z, Yang Y, Xin S, Li BA.
    Biochim Biophys Acta Gen Subj; 2018 Apr 29; 1862(4):1017-1030. PubMed ID: 29369785
    [Abstract] [Full Text] [Related]

  • 10. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N, Streit S, Wybranski C, Jürgens J, Brauner J, Schulz N, Powerski M, Ricke J, Kalinski T, Dudeck O, Seidensticker M.
    Anticancer Res; 2017 Jan 29; 37(1):87-93. PubMed ID: 28011478
    [Abstract] [Full Text] [Related]

  • 11. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Mao K, Zhang J, He C, Xu K, Liu J, Sun J, Wu G, Tan C, Zeng Y, Wang J, Xiao Z.
    Cancer Lett; 2014 Oct 01; 352(2):245-52. PubMed ID: 25034398
    [Abstract] [Full Text] [Related]

  • 12. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z, Yuan X, Qu Y, Li X, Wu G, Li C, Zu X, Yang N, Ke X, Zhou J, Xie N, Xu X, Liu S, Shen Y, Li H, Zhang W.
    Cancer Lett; 2017 Sep 10; 403():195-205. PubMed ID: 28645563
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
    Kim HY, Jung HU, Yoo SH, Yoo KS, Cheong J, Park BS, Yun I, Yoo YH.
    Cancer Lett; 2014 Dec 01; 355(1):61-9. PubMed ID: 25218348
    [Abstract] [Full Text] [Related]

  • 15. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK.
    Hepatology; 2015 Aug 01; 62(2):534-45. PubMed ID: 25902734
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ.
    Oncotarget; 2016 Dec 20; 7(51):85450-85463. PubMed ID: 27863427
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM, Yin XY, Lai YR, Hou X, Cai JP, Hao XY, Liang LJ, Zhang LJ.
    Cancer Chemother Pharmacol; 2013 May 20; 71(5):1255-64. PubMed ID: 23435877
    [Abstract] [Full Text] [Related]

  • 18. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF.
    Cancer Lett; 2016 Feb 28; 371(2):205-13. PubMed ID: 26679051
    [Abstract] [Full Text] [Related]

  • 19. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 20. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, Butte AJ, So S.
    Gastroenterology; 2017 Jun 08; 152(8):2022-2036. PubMed ID: 28284560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.